CDKN2A and progeroid syndrome: One study has shown that treatment with a HSP90 inhibitor (alvespimycin) for one week reduces the senescence marker p16INK4a/Cdkn2a by 60% in mouse kidneys with accelerated ageing (progeroid syndrome) [13].